Description

14-o-Acetyldoxorubicin is a semi-synthetic derivative of the potent anthracycline antibiotic doxorubicin, modified at the 14-O position with an acetyl group. This structural modification is significant for research into altering the pharmacokinetics, reducing cardiotoxicity, and exploring novel mechanisms of action of this important chemotherapeutic class. It serves as a critical pharmaceutical intermediate and reference standard in oncology research and drug development. This compound is primarily utilized by research institutions, pharmaceutical R&D laboratories, and manufacturers of active pharmaceutical ingredients (APIs) focused on anticancer therapies.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel doxorubicin analogs and prodrugs for cancer treatment.
• Oncology Research: Used as a reference compound in biochemical and pharmacological studies to investigate structure-activity relationships (SAR) of anthracyclines.
• Mechanistic Studies: Employed in research to understand and potentially mitigate the dose-limiting cardiotoxic side effects associated with doxorubicin therapy.
• Drug Metabolism & Pharmacokinetics (DMPK): Serves as a metabolite analog or standard in studies examining the biotransformation pathways of doxorubicin.
• Analytical Reference Standard: Provides a high-purity benchmark for quality control (QC) and analytical method development (e.g., HPLC, LC-MS) in API manufacturing.
• Academic & Institutional Research: Supports fundamental research in medicinal chemistry and molecular biology focused on DNA intercalation and topoisomerase II inhibition.

Basic Information

Product Name	14-o-Acetyldoxorubicin
CAS No.	30489-04-4
Molecular Formula	C₂₇H₂₉NO₁₁
Molecular Weight	543.52 g/mol
Synonyms	14-O-Acetyldoxorubicin; 14-Acetyldoxorubicin; Doxorubicin 14-acetate; AD 143; NSC 351393; (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 14-acetate
EINECS	Contact for details

Quality Control

Our 14-o-Acetyldoxorubicin is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation by spectroscopic methods (IR, NMR, MS). We provide full traceability and Certificates of Analysis (COA) are available for every shipment, detailing all critical quality attributes. Our production adheres to cGMP guidelines where applicable, ensuring consistency and reliability for research and development purposes.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or under refrigeration (2-8°C) as specified. This product is hygroscopic (moisture-sensitive) and easily oxidized; it is recommended to store under an inert atmosphere (e.g., nitrogen or argon) in a desiccated environment for long-term stability. Keep away from strong oxidizing agents.

Specification

Item	Specification
Appearance	Orange-red to red powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 2.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.